CN Patent

CN106928184B — 一种艾乐替尼的制备方法

Assigned to Hunan Runxing Pharmaceutical Co ltd · Expires 2019-09-20 · 7y expired

What this patent protects

本发明公开了一种艾乐替尼的制备方法。该方法将4‑(4‑乙基‑3‑碘苯基)‑4‑甲基‑3‑氧代戊酸叔丁酯与4‑(4‑哌啶基)吗啉进行取代反应;将得到的4‑{4‑乙基‑3‑[4‑(吗啉‑4‑基)哌啶‑1‑基]苯基}‑4‑甲基‑3‑氧代戊酸叔丁酯进行环化反应和水解反应,将得到的6‑氰基‑2‑{2‑[4‑乙基‑3‑(4‑(吗啉‑4‑基)哌啶‑1‑基)苯基]丙‑2‑基}‑1H‑吲哚‑3‑羧酸进行环化反应,得到艾乐替尼。该方法操作简化,成本较低,是一种绿色环保工艺方法,适用于工业化生产。

USPTO Abstract

本发明公开了一种艾乐替尼的制备方法。该方法将4‑(4‑乙基‑3‑碘苯基)‑4‑甲基‑3‑氧代戊酸叔丁酯与4‑(4‑哌啶基)吗啉进行取代反应;将得到的4‑{4‑乙基‑3‑[4‑(吗啉‑4‑基)哌啶‑1‑基]苯基}‑4‑甲基‑3‑氧代戊酸叔丁酯进行环化反应和水解反应,将得到的6‑氰基‑2‑{2‑[4‑乙基‑3‑(4‑(吗啉‑4‑基)哌啶‑1‑基)苯基]丙‑2‑基}‑1H‑吲哚‑3‑羧酸进行环化反应,得到艾乐替尼。该方法操作简化,成本较低,是一种绿色环保工艺方法,适用于工业化生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN106928184B
Jurisdiction
CN
Classification
Expires
2019-09-20
Drug substance claim
No
Drug product claim
No
Assignee
Hunan Runxing Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.